Investigating metabolic and immune changes in cancer patients with cachexia
Metabolic and Immunological Phenotyping in Patients With Cancer
This study looks at the changes in metabolism and immune response in cancer patients who are losing weight due to cachexia to help find better treatments for them in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cambridge University Hospitals NHS Foundation Trust Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Cambridge, Cambridgeshire and 1 other locations) |
| Trial ID | NCT04285242 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the metabolic and immunological changes associated with cachexia in patients diagnosed with non-haematological cancer. Conducted at a single center, it will involve detailed assessments to understand the mechanisms behind weight loss in these patients. By identifying these changes, the study seeks to lay the groundwork for future treatments aimed at reversing cachexia and improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and over with a confirmed diagnosis of non-haematological cancer who can comply with study procedures.
Not a fit: Patients currently undergoing chemotherapy, taking immunosuppressive drugs, or with significant acute or chronic conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new treatments that effectively combat weight loss in cancer patients, enhancing their quality of life.
How similar studies have performed: While this study focuses on a specific aspect of cachexia in cancer, similar observational studies have shown promise in understanding metabolic changes in cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have given written informed consent to participate * Be aged 18 years or over at the time of signing the informed consent form * Have a histological or cytological diagnosis of a non-haematological cancer * Are willing and able to comply with study procedures and visits Exclusion Criteria: * Active infection, as determined by the investigator based on clinical symptoms and / or fever and / or requirement for antibiotics * Current treatment with chemotherapy, oral steroids or other immunosuppressive drugs (within 7 days of baseline investigations or during the study phase) * Significant acute, chronic or psychiatric condition or laboratory abnormality which in the judgment of the investigator would place the patient at undue risk or interfere with the study. * Intolerance to dairy products * Women, who are pregnant, plan to become pregnant or are lactating
Where this trial is running
Cambridge, Cambridgeshire and 1 other locations
- Addenbrooke's Hospital, Cambridge University Hospitals Foundation Trust, — Cambridge, Cambridgeshire, United Kingdom (Recruiting)
- Cambridge University Hospitals NHS Foundation Trust — Cambridge, England, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Claire Connell — University of Cambridge
- Study coordinator: Early Phase Team Cambridge Cancer Trials Unit - Cancer Theme
- Email: cuh.cctuep@nhs.net
- Phone: 01223216083
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.